Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,449,641
  • Shares Outstanding, K 47,093
  • Annual Sales, $ 90,270 K
  • Annual Income, $ -372,880 K
  • 60-Month Beta 2.92
  • Price/Sales 80.76
  • Price/Cash Flow N/A
  • Price/Book 8.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -3.14
  • Number of Estimates 9
  • High Estimate -2.66
  • Low Estimate -3.57
  • Prior Year -1.68
  • Growth Rate Est. (year over year) -86.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
145.21 +8.04%
on 02/20/19
162.00 -3.16%
on 02/19/19
-4.05 (-2.52%)
since 02/15/19
3-Month
79.88 +96.39%
on 12/24/18
162.00 -3.16%
on 02/19/19
+58.33 (+59.19%)
since 12/18/18
52-Week
79.88 +96.39%
on 12/24/18
188.82 -16.92%
on 04/10/18
-15.34 (-8.91%)
since 03/16/18

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Sage Therapeutic After 2.82% Gain

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $152.86 to a high of $155.31. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high...

SAGE : 156.88 (-0.83%)
Market Trends Toward New Normal in Macy's, Comerica, JetBlue Airways, Intersect ENT, Stanley Black & Decker, and Sage Therapeutics -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Macy's, Inc. (NYSE:M), Comerica...

JBLU : 16.63 (-0.66%)
CMA : 82.90 (+0.77%)
SWK : 134.19 (+2.04%)
XENT : 33.64 (-1.00%)
SAGE : 156.88 (-0.83%)
M : 23.89 (+0.76%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics(NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that,...

SAGE : 156.88 (-0.83%)
Sage Therapeutics Announces Closing of $575 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the...

SAGE : 156.88 (-0.83%)
Sage Therapeutics Announces Proposed Public Offering of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 156.88 (-0.83%)
Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

--Topline data from Phase 3 trial of SAGE-217 in MDD expected in Q4 2019 or 1Q 2020

SAGE : 156.88 (-0.83%)
SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 19, 2019 / SAGE Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019 at 8:00...

SAGE : 156.88 (-0.83%)
Factors of Influence in 2019, Key Indicators and Opportunity within New Relic, Clean Harbors, Sage Therapeutics, Accelerate Diagnostics, Fortinet, and Colfax -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of New Relic, Inc. (NYSE:NEWR),...

CFX : 29.28 (+3.32%)
AXDX : 20.01 (+0.96%)
FTNT : 84.51 (+1.50%)
NEWR : 103.81 (-0.21%)
SAGE : 156.88 (-0.83%)
CLH : 69.39 (+0.95%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics(NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that,...

SAGE : 156.88 (-0.83%)
SmarTrend Watching for Potential Pullback in Shares of Sage Therapeutic After 2.06% Gain

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $142.81 to a high of $145.97. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high...

SAGE : 156.88 (-0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade SAGE with:

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

2nd Resistance Point 164.67
1st Resistance Point 160.78
Last Price 156.88
1st Support Level 153.99
2nd Support Level 151.10

See More

52-Week High 188.82
Last Price 156.88
Fibonacci 61.8% 147.20
Fibonacci 50% 134.35
Fibonacci 38.2% 121.50
52-Week Low 79.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar